which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. Novo Nordisk also gets rights to the ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes ... Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio ...

“Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its potential to improve health in obesity, heart disease and liver diseas ...

executive vice president of Product & Portfolio Strategy at Novo Nordisk. "Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

Novo Nordisk NVO had earlier acquired Prothena’s clinical-stage antibody, Coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis ...

Data across obesity, cardiovascular disease ... at Novo Nordisk. “Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its ...

"I had been living in a bubble, which I think a lot of women are,” she tells PEOPLE during Women's Health Month Theo Wargo/Getty Star Jones opens up to PEOPLE about her heart disease diagnosis ...

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...